• 1
    Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):17231735.
  • 2
    Coudray N, De Zuttere D, Force G, et al. Left ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: an echocardiographic study. Eur Heart J. 1995;16(1):6167.
  • 3
    Longo-Mbenza B, Seghers LV, Vita EK, et al. Assessment of ventricular diastolic function in AIDS patients from Congo: a Doppler echocardiographic study. Heart. 1998;80(2):184189.
  • 4
    Himelman RB, Chung WS, Chernoff DN, et al. Cardiac manifestations of human immunodeficiency virus infection: a two-dimensional echocardiographic study. J Am Coll Cardiol. 1989;13(5):10301036.
  • 5
    Anderson DW, Virmani R, Reilly JM, et al. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol. 1988;11(4):792799.
  • 6
    Restrepo CS, Diethelm L, Lemos JA, et al. Cardiovascular complications of human immunodeficiency virus infection. Radiographics. 2006;26(1):213231.
  • 7
    Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol. 1990;66(2):203206.
  • 8
    De Castro S, Migliau G, Silvestri A, et al. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J. 1992;13(11):14521459.
  • 9
    Currie PF, Jacob AJ, Foreman AR, et al. Heart muscle disease related to HIV infection: prognostic implications. BMJ. 1994;309(6969):16051607.
  • 10
    Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect. 2000;40(3):282284.
  • 11
    Meng Q, Lima JA, Lai H, et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr. 2002;30(3):306310.
  • 12
    Mittal CM, Wig N, Mishra S, et al. Cardiac dysfunction in human immunodeficiency virus (HIV) infected patients in India. Int J Cardiol. 2006;107(1):136137.
  • 13
    Cade WT, Reeds DN, Davila V, et al. Heart rate recovery is associated with resting diastolic dysfunction in HIV+. FASEB J. 2006;20:A741.
  • 14
    Martinez-Garcia T, Sobrino JM, Pujol E, et al. Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus. Heart. 2000;84(6):620624.
  • 15
    Cardoso JS, Moura B, Martins L, et al. Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. Int J Cardiol. 1998;63(1):3745.
  • 16
    Lipshultz SE, Easley KA, Orav EJ, et al. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation. 1998;97(13):12461256.
  • 17
    Lipshultz SE, Easley KA, Orav EJ, et al. Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation. 2000;102(13):15421548.
  • 18
    Lipshultz SE, Easley KA, Orav EJ, et al. Cardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): a cohort study. Lancet. 2002;360(9330):368373.
  • 19
    Calabrese LH, Proffitt MR, Yen-Lieberman B, et al. Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Ann Intern Med. 1987;107(5):691692.
  • 20
    Lipshultz SE, Fox CH, Perez-Atayde AR, et al. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome. Am J Cardiol. 1990;66(2):246250.
  • 21
    Morgello S, Mahboob R, Yakoushina T, et al. Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. Arch Pathol Lab Med. 2002;126(2):182190.
  • 22
    Chang WT, Wu CC, Hung CC, et al. Left ventricular dysfunction is associated with CD4 lymphocyte count rather than opportunistic infection in human immunodeficiency virus infection. J Formos Med Assoc. 2003;102(3):158163.
  • 23
    Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. 1991;325(22):15571564.
  • 24
    Fisher SD, Easley KA, Orav EJ, et al. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am Heart J. 2005;150(3):439447.
  • 25
    Barker DJ, Martyn CN. The maternal and fetal origins of cardiovascular disease. J Epidemiol Community Health. 1992;46(1):811.
  • 26
    Kay DG, Yue P, Hanna Z, et al. Cardiac disease in transgenic mice expressing human immunodeficiency virus-1 nef in cells of the immune system. Am J Pathol. 2002;161(1):321335.
  • 27
    Raidel SM, Haase C, Jansen NR, et al. Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol Heart Circ Physiol. 2002;282(5):H1672H1678.
  • 28
    Lewis W, Miller YK, Haase CP, et al. HIV viral protein R causes atrial cardiomyocyte mitosis, mesenchymal tumor, dysrhythmia, and heart failure. Lab Invest. 2005;85(2):182192.
  • 29
    Morgello S, Wolfe D, Godfrey E, et al. Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy. Acta Neuropathol (Berl). 1995;90(4):366374.
  • 30
    Boudina S, Sena S, O'Neill BT, et al. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation. 2005;112(17):26862695.
  • 31
    Lewis W, Papoian T. Molecular mechanisms of heart muscle disease. West J Med. 1991;154(1):91.
  • 32
    Lewis W, Papoian T, Gonzalez B, et al. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest. 1991;65(2):228236.
  • 33
    Gerschenson M, Poirier MC. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. Ann N Y Acad Sci. 2000;918:269281.
  • 34
    Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 1991;337(8740):508510.
  • 35
    Weissman JD, Constantinitis I, Hudgins P, et al. 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients. Neurology. 1992;42(3, pt 1):619623.
  • 36
    Wisloff U, Najjar SM, Ellingsen O, et al. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science. 2005;307(5708):418420.
  • 37
    Wei M, Kampert JB, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normalweight, overweight, and obese men. JAMA. 1999;282(16):15471553.
  • 38
    Claessens YE, Chiche JD, Mira JP, et al. Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Crit Care. 2003;7(3):226232.
  • 39
    Domanski MJ, Sloas MM, Follmann DA, et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr. 1995;127(1):137146.
  • 40
    Wang X, Chai H, Yao Q, et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr. 2007;44(5):493499.
  • 41
    Conklin BS, Fu W, Lin PH, et al. HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovasc Res. 2004;63(1):168175.
  • 42
    Zhong DS, Lu XH, Conklin BS, et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22(10):15601566.
  • 43
    Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365(9460):682686.
  • 44
    Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):4862.
  • 45
    Iozzo P, Chareonthaitawee P, Dutka D, et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes. 2002;51(10):30203024.
  • 46
    Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):27092716.
  • 47
    De Las Fuentes L, Brown AL, Mathews SJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J. 2007;28(5):553559.
  • 48
    Hogg K, McMurray J. The treatment of heart failure with preserved ejection fraction (“diastolic heart failure”). Heart Fail Rev. 2006;11(2):141146.
  • 49
    Cade WT, Peralta L, Keyser RE. Aerobic exercise dysfunction in human immunodeficiency virus: a potential link to physical disability. Phys Ther. 2004;84(7):655664.
  • 50
    Stewart KJ, Ouyang P, Bacher AC, et al. Exercise effects on cardiac size and left ventricular diastolic function: relationships to changes in fitness, fatness, blood pressure and insulin resistance. Heart. 2006;92(7):893898.
  • 51
    Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006;20(7):10191026.
  • 52
    Hansen BR, Haugaard SB, Iversen J, et al. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis. 2004;36(4):244253.